Kaleido Biosciences, Inc. (KLDO)
| Market Cap | 248.23M |
| Revenue (ttm) | 1.23M |
| Net Income (ttm) | -90.08M |
| Shares Out | 42.58M |
| EPS (ttm) | -2.34 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 358,664 |
| Open | 5.49 |
| Previous Close | 5.45 |
| Day's Range | 5.43 - 5.93 |
| 52-Week Range | 5.04 - 20.50 |
| Beta | -0.32 |
| Analysts | Buy |
| Price Target | 18.00 (+208.7%) |
| Est. Earnings Date | Nov 2, 2021 |
About KLDO
Kaleido Biosciences, Inc., a clinical-stage healthcare company, develops microbiome metabolic therapies. The company develops KB195 for the treatment of patients with urea cycle disorder; KB295 to treat ulcerative colitis; KB174 for the treatment of hepatic encephalopathy; and KB109 to treat COVID-19 disease. It also develops programs for the treatment of immuno-oncology, and cardiometabolic and liver diseases. The company has collaboration agreements with Gustave Roussy Cancer Center, Washington University School of Medicine, and Janssen. It a...
Financial Performance
Financial StatementsAnalyst Forecast
According to 7 analysts, the average rating for KLDO stock is "Buy." The 12-month stock price forecast is 18.00, which is an increase of 208.75% from the latest price.
News
FDA Questions Kaleido Biosciences 'Non-IND' COVID-19 Trial
The FDA has issued a warning letter to Kaleido Biosciences Inc (NASDAQ: KLDO), blasting its “failure to submit Investigational New Drug applications for a clinical trial with an investigational new drug...
Kaleido Biosciences to Participate in the Morgan Stanley 19th Annual Virtual Global Healthcare Conference
LEXINGTON, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micro...
Kaleido Biosciences, Inc. (KLDO) Reports Q2 Loss, Lags Revenue Estimates
Kaleido Biosciences, Inc. (KLDO) delivered earnings and revenue surprises of 5.08% and -15.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Kaleido Biosciences Reports Second Quarter 2021 Financial Results
--On track to report topline data from a clinical study of KB295 in patients with mild-to-moderate ulcerative colitis by end of third quarter-- --Kaleido and the COPD Foundation to collaborate on the de...
Kaleido Biosciences and the COPD Foundation Announce a Strategic Collaboration to Advance KB109 into Phase 2 Clinical...
On track to initiate Phase 2 trial in the first quarter of 2022 On track to initiate Phase 2 trial in the first quarter of 2022
Kaleido Biosciences Announces New Chairperson Appointment to its Board of Directors
Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors Current Director Theo Melas-Kyriazi appointed Chairperson of the Board of Directors
Kaleido Biosciences to Participate in the 41st Annual Canaccord Genuity Growth Conference
LEXINGTON, Mass., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
Kaleido Biosciences, Inc. (KLDO) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Kaleido Biosciences, Inc. (KLDO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Kaleido Biosciences to Participate in the JMP Securities Life Sciences Conference
LEXINGTON, Mass., June 10, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
Kaleido Biosciences Reports First Quarter 2021 Financial Results
--Positive results in patients with mild-to-moderate COVID-19 demonstrate KB109's potential to reduce healthcare utilization and recovery time; initiating IND application to support further development-...
Kaleido Biosciences Announces Collaboration with Robert Jenq, M.D., to Explore Potential of its Microbiome Metabolic ...
LEXINGTON, Mass., April 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a small molecule driven approach to targeting the microbiome to tr...
Kaleido Biosciences to Participate in Jefferies Microbiome-Based Therapeutics Summit
LEXINGTON, Ma., April 15, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microbi...
Biotech company Kaleido develops oral therapy for COVID-19
Dan Menichella, Kaleido CEO, joins Yahoo Finance's Anjalee Khemlani, Alexis Christoforous and Kristin Myers to discuss the utilization of oral therapeutic KB109 for COVID-19 and emerging variants.
Kaleido (KLDO) Reports Positive Results from COVID-19 Study
Kaleido (KLDO) announces impressive results from a study on KB109 in patients with mild-to-moderate COVID-19.
Kaleido Biosciences Stock Is Trading Higher On Positive KB109 Data In COVID-19 Study
Kaleido Biosciences Inc (NASDAQ: KLDO) reported positive results from a non-IND study of KB109 in patients with mild-to-moderate COVID-19. KB109 demonstrated an overall favorable safety and tolerability...
Kaleido Biosciences Reports Positive Results from Non-IND Study Demonstrating a Reduction in COVID-19 Related Healthc...
KB109 demonstrated favorable safety and tolerability profile
Kaleido Biosciences Reports Fourth Quarter and Full Year 2020 Financial Results
Topline data from two ongoing COVID-19 studies with KB109 expected in Q1 2021
Kaleido Biosciences to Present at Chardan's 3rd Annual Microbiome Medicines Summit
LEXINGTON, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the micro...
Cellarity Raises $123 Million in Series B Funding to Pioneer a New Approach to Drug Discovery, Treating Disease at th...
CAMBRIDGE, Mass., Feb. 25, 2021 /PRNewswire/ -- Cellarity, a life sciences company founded by Flagship Pioneering to develop a new method of drug discovery targeting the cell, announced today that it ra...
Kaleido Biosciences (KLDO) Sees Hammer Chart Pattern: Time to Buy?
Kaleido Biosciences (KLDO) has been struggling lately, but the selling pressure may be coming to an end soon.
Kaleido Biosciences Announces the Exercise of the Underwriters' Option to Purchase Additional Shares of Common Stock
LEXINGTON, Mass., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
Why Corcept Therapeutics, Acasti Pharma And More Are Moving Today
Corcept Therapeutics (NASDAQ: CORT) shares were trading lower Tuesday after the company reported preliminary fourth-quarter sales results and issued fiscal year 2021 sales guidance. Corcept Therapeutics...
Kaleido Biosciences Announces Pricing of Public Offering of Common Stock
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
Kaleido Biosciences Announces Proposed Public Offering of Common Stock
LEXINGTON, Mass., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a differentiated, chemistry-driven approach to targeting the microb...
Kaleido Biosciences to Present at the Keystone Symposium “Harnessing the Microbiome for Disease Prevention and Therap...
LEXINGTON, Mass., Jan. 20, 2021 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced Johan van Hylckama Vlieg, Ph.D., Chief Scientific Officer, will present at the Keystone Symp...